Ipamorelin UK: Research Status, Testing & UK Peptides
Ipamorelin UK Explained: Research Status, Testing and UK Peptides
Ipamorelin is frequently described online as a growth hormone peptide. That phrase is both incomplete and potentially misleading. Ipamorelin is not growth hormone, and it does not belong to the same peptide family as Sermorelin or CJC 1295. It is a short, synthetic research peptide associated with the ghrelin receptor pathway.
Ipamorelin at a Glance
Ipamorelin has a genuine scientific history, but that history is often misrepresented by commercial pages that make claims far beyond the published evidence.
What Is Ipamorelin?
Ipamorelin is a synthetic peptide made from five amino acid related building blocks. A peptide containing five residues is called a pentapeptide.
The sequence is commonly represented as:
Aib His D 2 Nal D Phe Lys NH2
Ipamorelin is also known by the development code NNC 26 0161. PubChem records its molecular formula as C38H49N9O5 and lists a molecular weight of approximately 711.9 grams per mole. 1
In simple language: Ipamorelin is a very short laboratory designed peptide that interacts with a receptor also used by the naturally occurring hormone ghrelin.
Is Ipamorelin Growth Hormone?
No.
Growth hormone is a much larger protein consisting of 191 amino acids in its principal human form. Ipamorelin is a five residue synthetic peptide.
Ipamorelin is described as a secretagogue because it was investigated for its ability to activate a signalling pathway associated with hormone release. It is not the hormone itself.
Calling Ipamorelin “growth hormone” is rather like calling a doorbell the person who answers the door. One may trigger a signal, but they are not the same object.
Why a Five Residue Peptide Is Not Necessarily Simple
Ipamorelin is short, but its chemical identity involves more than counting five ordinary amino acids.
Several positions use non standard or stereochemically specified residues. These include:
- Aib: alpha aminoisobutyric acid, a non standard amino acid
- D 2 Nal: a D configured naphthylalanine related residue
- D Phe: the D form of phenylalanine
- NH2: a terminal amide rather than an unmodified acid ending
These details matter because a product could contain five residues and still be the wrong molecule if:
- The residues appear in the wrong order
- The D and L configurations are incorrect
- The terminal form is wrong
- A related aromatic residue has been substituted
- The expected molecular mass does not match
An abbreviation such as IP5 may suggest Ipamorelin with a nominal quantity, but it does not establish the scientific identity of the material.
What Is the Ghrelin Receptor Pathway?
Understanding the receptor explains why Ipamorelin differs from Sermorelin and CJC 1295, even though all three names are often grouped together online.
Ghrelin
Ghrelin is a naturally occurring peptide hormone first reported in 1999 as an endogenous ligand for the growth hormone secretagogue receptor. 2
It is a considerably larger and chemically different molecule from Ipamorelin.
GHSR 1a
The growth hormone secretagogue receptor type 1a is a cell surface receptor involved in ghrelin related signalling.
Ipamorelin was designed as a synthetic agonist of this receptor pathway.
Ipamorelin
The original pharmacology paper described Ipamorelin as a selective growth hormone secretagogue receptor agonist. 3
That classification describes laboratory receptor activity. It does not establish a consumer use or clinical benefit.
GHRH Analogues
Sermorelin and CJC 1295 are associated with the growth hormone releasing hormone receptor rather than the ghrelin receptor.
Grouping them together under “growth hormone peptides” hides this important difference.
What Did the Original Selectivity Research Show?
The 1998 paper compared Ipamorelin with other growth hormone releasing peptides in laboratory and animal models.
The authors described Ipamorelin as having a more selective secretagogue profile than some earlier compounds within the models tested.
That finding should not be rewritten as:
- Free from side effects
- Safe for long term use
- Safer than every related peptide
- Suitable for self administration
- Clinically proven for body composition or physical performance
Selectivity at a receptor pathway is not the same as complete clinical safety.
What Has Ipamorelin Actually Been Studied For?
Much of the online discussion associates Ipamorelin with fitness and anti ageing. Its visible human clinical development followed a very different route.
Early Pharmacology
Early studies focused on receptor selectivity, pharmacokinetics and the relationship between Ipamorelin exposure and measurable hormone responses.
These studies helped characterise the molecule but did not approve it for personal use.
Gastrointestinal Research
Later research examined Ipamorelin as a ghrelin receptor agonist in models involving gastrointestinal movement after surgery.
ClinicalTrials.gov records Phase 2 research involving postoperative gastrointestinal recovery. 4
This historical research is important because it contradicts the simplified online story that Ipamorelin was developed primarily as a bodybuilding, recovery or anti ageing compound.
The Published Proof of Concept Trial
A multicentre, double blind, placebo controlled study was published in 2014. It included adults undergoing bowel resection. 5
The study did not find statistically significant differences between Ipamorelin and placebo in its key or secondary efficacy analyses.
This is a useful reminder that:
- A plausible biological mechanism does not guarantee a successful clinical outcome.
- Promising animal findings may not translate into meaningful human results.
- Being evaluated in a Phase 2 trial does not mean that a compound became an approved medicine.
- Clinical development for one proposed use does not validate unrelated online claims.
The Research History in One Sentence
Ipamorelin has established receptor pharmacology and limited human research, but the controlled proof of concept study did not demonstrate significant differences in its main efficacy analyses and did not lead to an identified UK authorisation.
How Strong Is the Evidence?
A balanced account separates molecular activity from established clinical usefulness.
Receptor Studies
These help establish whether Ipamorelin interacts with the intended receptor pathway.
Animal Models
These explore whole organism responses but cannot establish safety or usefulness in people.
Early Human Studies
These characterised pharmacological responses under controlled research conditions.
Phase 2 Evidence
The published proof of concept trial did not show significant differences in key efficacy analyses.
What Evidence Is Missing?
The sources reviewed do not provide a basis for presenting Ipamorelin as an established product for:
- Muscle development
- Fat reduction
- Exercise recovery
- Improved sleep
- Reversing ageing
- Enhancing physical performance
- General wellness
- Hormone replacement
These phrases are listed to explain what the article does not claim. They must not be reused as promotional headings, meta keywords or product benefits.
Ipamorelin Compared with Other UK Peptides
The most helpful comparison is not which substance is “best”. It is how their molecular identities and receptor pathways differ.
| Material | What it is | Main research pathway | Key distinction |
|---|---|---|---|
| Ipamorelin | Synthetic pentapeptide | Ghrelin or growth hormone secretagogue receptor | Short peptide with non standard residues and a terminal amide |
| Ghrelin | Naturally occurring acylated peptide hormone | Ghrelin receptor | Natural endogenous ligand with a different sequence and chemical structure |
| GHRP 2 | Synthetic growth hormone releasing peptide | Ghrelin receptor | Different sequence and receptor activity profile |
| GHRP 6 | Synthetic hexapeptide | Ghrelin receptor | Six residue peptide with a different chemical identity |
| Hexarelin | Synthetic hexapeptide | Ghrelin receptor | Different sequence, potency profile and research history |
| Sermorelin | GHRH related peptide fragment | GHRH receptor | Uses a different receptor pathway from Ipamorelin |
| CJC 1295 | Modified GHRH analogue | GHRH receptor | Longer peptide with distinct DAC and No DAC forms |
| Ibutamoren | Small molecule secretagogue | Ghrelin receptor | Not a peptide despite acting within the same broad receptor system |
| Human growth hormone | Large protein hormone | Growth hormone receptor | The hormone itself rather than a secretagogue receptor agonist |
Ipamorelin Compared with Sermorelin
Sermorelin is related to growth hormone releasing hormone and interacts with the GHRH receptor.
Ipamorelin interacts with the ghrelin or growth hormone secretagogue receptor.
Both can appear in discussions concerning the same broader endocrine axis, but they are not interchangeable molecules and do not activate the same receptor.
Ipamorelin Compared with CJC 1295
CJC 1295 is a much longer, modified GHRH analogue. The term may also refer to forms with or without a drug affinity complex.
A CJC 1295 and Ipamorelin product is a blend containing separate molecular entities. It is not one newly created peptide.
Certificates for the separate ingredients do not automatically establish the ratio, homogeneity or identity of the finished blend.
Ipamorelin Compared with Ibutamoren
Both are associated with the ghrelin receptor pathway, but Ibutamoren is a small molecule rather than a peptide.
This means their manufacturing processes, analytical methods and impurity profiles may differ substantially.
Why Common Online Ipamorelin Claims Require Caution
Commercial websites frequently move from receptor pharmacology to confident claims about appearance, performance or wellbeing. That leap is not justified by the evidence reviewed for this article.
“Selective” Means Risk Free
Selectivity within an experimental receptor model does not prove complete safety, absence of unwanted effects or suitability for prolonged human use.
Mechanism Equals Outcome
Demonstrating receptor activity does not establish that an unlicensed product produces a useful clinical or personal result.
Research Means Approved
Human trials show that a question was investigated. They do not automatically create marketing authorisation.
Research Vial Equals Trial Product
An ecommerce vial bearing the same name has not automatically been manufactured or verified to the specification used in a controlled study.
Ipamorelin and UK Regulation
Legal classification cannot be determined from the words Research Use Only in isolation.
The Substance
Authorities may consider the molecular identity and known pharmacological characteristics.
The Claims
Explicit and implied claims can influence whether a product is presented as medicinal.
The Context
Images, reviews, website categories and links to purchase form part of the presentation.
The Expected Use
Authorities may consider how an ordinary customer is likely to understand and use it.
The MHRA Medicines Boundary
The MHRA decides whether a product falls within the definition of a medicinal product. 7
Its guidance says that decisions can consider:
“The claims about what the product does, explicit and implicit.”
MHRA borderline products guidance
A product may be regarded as medicinal when it is presented as treating or preventing disease, or where it is intended to modify a physiological function through pharmacological, immunological or metabolic action.
The following features could undermine a claimed laboratory only position:
- Human doses or cycles
- Injection or preparation instructions
- Claims about muscle, fat, recovery, sleep or ageing
- Before and after imagery
- Customer reviews describing physical effects
- Comparisons with authorised hormone treatments
- Administration equipment supplied beside the product
- Influencer content describing personal results
Advertising an Unauthorised Product
Regulation 279 of the Human Medicines Regulations states that an advertisement for a medicinal product cannot be published unless the relevant authorisation or registration is in force. 8
CAP Code Section 12 also states that marketing communications for an unlicensed product must not make medicinal or therapeutic claims unless authorised by the MHRA. 9
This is why the present article describes molecular identity, research history and regulatory context but does not provide benefits, treatment claims or consumer purchasing guidance.
UK REACH, Safety Data Sheets and COSHH
Where a substance is lawfully supplied as a laboratory chemical, medicines law may not be the only relevant framework.
UK REACH applies broadly to chemical substances manufactured in or imported into Great Britain, subject to its detailed scope and exemptions. 10
Appropriate classification, labelling, packaging, safety communication and workplace controls may also require assessment.
“A safety data sheet is not a risk assessment.”
Health and Safety Executive
A laboratory must use safety information to complete its own COSHH assessment, taking account of exposure routes, procedures, controls, storage and disposal. 11
Ipamorelin and Competitive Sport
Ipamorelin is explicitly named on the World Anti Doping Agency’s 2026 Prohibited List under growth hormone secretagogues and their mimetics. 12
Its anti doping status is separate from UK marketing authorisation and medicines classification.
A substance can be prohibited in sport without being an approved medicine. A research label, supplement label or supplier assurance does not remove an athlete’s anti doping responsibility.
Athletes and support personnel should check substances through their governing body, UK Anti Doping or another applicable official anti doping authority.
How Is Ipamorelin Identified in Laboratory Research?
Its short length does not make identity testing optional. The non standard residues and stereochemistry make accurate characterisation particularly important.
Chromatography can separate detectable components and report the relative area associated with the principal peak.
Mass analysis can assess whether the observed molecular mass is consistent with the stated Ipamorelin structure.
Additional or orthogonal methods may be needed where the research requires confirmation of residue order or stereochemical identity.
What Should a Research Certificate Identify?
- The complete product name
- The alternative code NNC 26 0161 where relevant
- The stated sequence
- The D and L configurations
- The terminal amide
- The expected molecular mass
- The observed identity result
- The chromatographic method and purity result
- The batch or lot number
- The date of analysis
- The issuing laboratory or manufacturer
- A traceable report number
What Does 99 Per Cent HPLC Purity Mean?
It ordinarily refers to the proportion of detected chromatographic peak area assigned to the principal peak under the stated method.
It does not automatically prove:
- That the main peak is Ipamorelin
- That every residue has the correct stereochemistry
- That the vial contains the stated absolute mass
- That the product is sterile
- That endotoxin levels have been assessed
- That the product is suitable for administration
A short peptide still requires a complete identity. Five residues in the wrong form are not Ipamorelin.
Due Diligence for Authorised Institutional Research
This is not a consumer buying guide. It describes governance questions for appropriately authorised laboratories and research institutions.
Define the Research Purpose
The institution should document why Ipamorelin is required and how it relates to an approved project.
Review Legal Requirements
Medicines, chemical, import, ethical and institutional requirements should be assessed before acquisition.
Verify the Legal Source
The manufacturer, importer, distributor and responsible quality contacts should be identifiable.
Confirm the Exact Sequence
The non standard residues, stereochemistry and terminal form should be disclosed accurately.
Match the Batch
Analytical documents must relate to the material actually received rather than a sample or historic certificate.
Review Identity and Purity
HPLC purity should be considered alongside an appropriate molecular identity method.
Assess Quantity Evidence
The institution should understand whether a stated quantity means net peptide, total material or a nominal filling target.
Complete COSHH Assessment
Handling, exposure, controls, storage, emergency procedures and waste should be assessed locally.
Control Access
Research material should be stored under appropriate institutional custody and access restrictions.
Maintain Traceability
Receipt, use, transfer and disposal records should be retained where required.
Check Anti Doping Relevance
Institutions involving athletes should recognise Ipamorelin’s expressly prohibited status.
Prohibit Personal Use
Institutional research material must not be diverted into self experimentation or unauthorised administration.
Medical and Editorial Review
This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide transparent authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a professional background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a professional interest in nutritional sciences, dietology, metabolic health and evidence-based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient-centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board-certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence-based aesthetic care.
Read professional profileFrequently Asked Questions About Ipamorelin UK
Straightforward answers without treatment, administration or purchasing advice.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide and agonist of the ghrelin or growth hormone secretagogue receptor pathway.
What is another name for Ipamorelin?
Its development code is NNC 26 0161, sometimes written as NNC 26-0161.
Is Ipamorelin growth hormone?
No. Human growth hormone is a large protein. Ipamorelin is a five residue synthetic secretagogue peptide.
Is Ipamorelin the same as ghrelin?
No. Ghrelin is a naturally occurring acylated peptide hormone. Ipamorelin is a separate synthetic molecule designed to interact with the same broad receptor pathway.
Is Ipamorelin the same as Sermorelin?
No. Sermorelin is related to growth hormone releasing hormone and acts through the GHRH receptor. Ipamorelin acts through the ghrelin receptor pathway.
Is Ipamorelin the same as CJC 1295?
No. CJC 1295 is a longer modified GHRH analogue. A CJC 1295 and Ipamorelin product is a blend of separate materials.
Is Ibutamoren a peptide like Ipamorelin?
No. Ibutamoren is a small molecule rather than a peptide, although it is associated with the same broad receptor pathway.
Was Ipamorelin studied in people?
Yes. Historical controlled research included studies of pharmacology and postoperative gastrointestinal recovery.
The published proof of concept trial did not find significant differences in its key efficacy analyses.
Is Ipamorelin an authorised UK medicine?
No UK marketing authorisation was identified in the official sources reviewed for this article on 17 July 2026.
Can Research Use Only make every Ipamorelin sale lawful?
No. The MHRA may consider the substance, claims, imagery, intended purpose, likely use and wider commercial presentation.
Is Ipamorelin prohibited in sport?
Yes. Ipamorelin is expressly named on the World Anti Doping Agency’s 2026 Prohibited List.
Does HPLC prove that a sample is Ipamorelin?
Not by itself. HPLC provides chromatographic information, while molecular identity requires suitable supporting analysis.
Does 99 per cent purity prove that 99 per cent of the vial is Ipamorelin?
Not necessarily. HPLC area purity, molecular identity, net peptide content and total vial mass are separate measurements.
Does a COA prove that Ipamorelin is suitable for administration?
No. A Certificate of Analysis reports only the tests stated on it. It does not automatically establish sterility, authorisation or suitability for human or veterinary use.
Why is there no consumer buying guide?
A consumer supplier guide could encourage the acquisition or personal use of an unauthorised pharmacologically active compound. This article therefore limits procurement discussion to appropriately governed institutional research.
Does this article recommend using Ipamorelin?
No. It provides neutral information about molecular identity, evidence, analytical testing, regulation and anti doping status.
The Balanced View
Ipamorelin is a real synthetic peptide with an established receptor pharmacology history. It is not simply an invented internet product name.
It is also not growth hormone, not a GHRH analogue and not an authorised answer to the performance, body composition or anti ageing claims commonly attached to it online.
Historical clinical research examined a specific gastrointestinal question under controlled conditions. The published proof of concept trial did not demonstrate significant differences in its key efficacy analyses.
For responsible readers, the most useful conclusions are therefore:
- Ipamorelin is a five residue synthetic ghrelin receptor agonist.
- Its short sequence includes non standard and stereochemically defined residues.
- Its mechanism should not be turned into unproven consumer benefits.
- An online vial is not automatically equivalent to historical trial material.
- Research Use Only does not override UK medicines or advertising law.
- Ipamorelin is expressly prohibited under current anti doping rules.
- Identity, purity, quantity and sterility are separate analytical questions.
The careful question is not what an online peptide page promises Ipamorelin will do. It is what the evidence and documentation can genuinely establish.
Scientific and Official Sources
- PubChem: Ipamorelin compound identity, synonyms, sequence representation and molecular data
- Kojima M and colleagues: Ghrelin is a growth hormone releasing acylated peptide from the stomach
- Raun K and colleagues: Ipamorelin, the first selective growth hormone secretagogue
- ClinicalTrials.gov: Ipamorelin research following bowel resection
- ClinicalTrials.gov: Phase 2 dose finding research involving Ipamorelin
- Beck DE and colleagues: Controlled proof of concept study of Ipamorelin
- MHRA: Borderline products and how to tell if a product is a medicine
- Human Medicines Regulations 2012: Regulation 279
- CAP Code Section 12: Medicines, medical devices and health related products
- Health and Safety Executive: UK REACH explained
- Health and Safety Executive: Safety Data Sheets and COSHH
- Health and Safety Executive: How to carry out a COSHH risk assessment
- World Anti Doping Agency: 2026 Prohibited List
